TIL

+ Watchlist + Portfolio

Instil Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.39
52-Week Range: $5.67 – $33.83
Market Cap: $50.39M
P/E (TTM): —
EPS (TTM): -4.40
Dividend Yield: —

Advanced Metrics

Price/Book: 0.46
PEG Ratio: —
Return on Equity: -25.33%
Return on Assets: -10.77%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 21.67
Debt/Equity: 0.81
Total Debt: $87.03M
Free Cash Flow: $85.50M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $67.74M

TIL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$141.06M	$39.60M	$11.84M	$24.74M
Selling, General & Admin	$62.23M	$47.55M	$44.21M	$27.22M
Operating Expenses	$203.29M	$87.16M	$56.05M	$51.96M
Operating Income	-$203.29M	-$87.16M	-$56.05M	-$51.96M
EBITDA	-$217.38M	-$147.12M	-$62.53M	-$65.80M
Pretax Income	-$225.25M	-$156.09M	-$74.14M	-$71.37M
Income Tax	-$2.07M	$0.00	—	—
Net Income	-$223.18M	-$156.09M	-$74.14M	-$71.37M
Diluted EPS	-34.40	-24.00	-11.39	-10.70
Diluted Shares	6.48M	6.50M	6.51M	6.67M

TIL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.72M	$9.20M	$8.80M	$6.64M
Receivables	—	—	—	$848.00K
Current Assets	$269.38M	$160.76M	$124.47M	$191.43M
Total Assets	$482.13M	$325.63M	$263.57M	$203.52M
Current Liabilities	$32.79M	$10.56M	$7.90M	$4.84M
Long-Term Debt	$72.35M	$81.43M	$84.19M	$84.81M
Total Debt	$79.90M	$86.05M	$86.89M	$85.18M
Total Liabilities	$118.52M	$99.80M	$94.13M	$89.66M
Retained Earnings	-$424.89M	-$580.98M	-$655.12M	-$726.49M
Shareholders' Equity	$363.61M	$225.83M	$169.44M	$113.87M
Working Capital	$236.59M	$150.20M	$116.57M	$186.59M
Net Debt	$28.63M	$72.23M	$75.38M	$78.17M

TIL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$180.16M	-$82.03M	-$55.70M	-$36.62M
Capital Expenditure	-$84.59M	-$20.66M	-$10.00M	-$10.00M
Free Cash Flow	-$264.75M	-$102.69M	-$65.70M	-$46.62M
Depreciation & Amortisation	$5.99M	$4.76M	$3.61M	$534.00K
Stock-Based Compensation	$30.44M	$18.17M	$17.26M	$8.69M
Investing Cash Flow	$114.54M	$41.13M	$53.97M	$25.48M
Financing Cash Flow	$71.89M	$8.08M	$1.75M	$7.29M
Net Change in Cash	$6.26M	-$32.82M	$33.00K	-$3.85M

TIL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.37M	$6.74M	$9.13M	$3.50M	$669.00K
Selling, General & Admin	$9.11M	$6.16M	$5.89M	$6.06M	$5.35M
Operating Expenses	$14.48M	$12.90M	$15.02M	$9.56M	$6.02M
Operating Income	-$14.48M	-$12.90M	-$15.02M	-$9.56M	-$6.02M
EBITDA	-$26.82M	-$19.80M	-$11.99M	-$7.40M	-$2.83M
Pretax Income	-$28.20M	-$21.39M	-$13.59M	-$8.19M	-$4.20M
Net Income	-$28.20M	-$21.39M	-$13.59M	-$8.19M	-$4.20M
Diluted EPS	-4.32	-3.24	-2.01	—	-0.62
Diluted Shares	6.53M	6.60M	6.76M	—	6.78M

TIL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$15.37M	$7.69M	$5.80M	$6.64M	$5.02M
Receivables	$924.00K	$805.00K	$843.00K	$848.00K	$28.00K
Current Assets	$219.26M	$207.39M	$196.26M	$191.43M	$188.30M
Total Assets	$237.45M	$230.99M	$211.77M	$203.52M	$200.43M
Current Liabilities	$7.23M	$13.85M	$5.70M	$4.84M	$4.72M
Long-Term Debt	$84.23M	$84.42M	$84.61M	$84.81M	$85.00M
Total Debt	$86.67M	$84.88M	$84.92M	$85.18M	$85.19M
Total Liabilities	$92.54M	$99.32M	$91.35M	$89.66M	$89.73M
Retained Earnings	-$683.32M	-$704.71M	-$718.30M	-$726.49M	-$730.69M
Shareholders' Equity	$144.91M	$131.67M	$120.42M	$113.87M	$110.70M
Working Capital	$212.03M	$193.53M	$190.57M	$186.59M	$183.58M
Net Debt	$68.86M	$76.73M	$78.81M	$78.17M	$79.98M

TIL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.20M	-$14.79M	-$10.56M	-$7.08M	-$1.34M
Free Cash Flow	-$4.20M	-$14.79M	-$20.56M	-$7.08M	-$1.34M
Depreciation & Amortisation	$498.00K	$12.00K	$12.00K	$12.00K	$12.00K
Stock-Based Compensation	$3.50M	$1.82M	$1.77M	$1.61M	$985.00K
Investing Cash Flow	$9.61M	-$400.00K	$8.45M	$7.82M	-$317.00K
Financing Cash Flow	$232.00K	$6.68M	$378.00K	$0.00	$0.00
Net Change in Cash	$5.65M	-$8.51M	-$1.73M	$742.00K	-$1.65M

Market Snapshot

About

Instil Bio, Inc. is a clinical-stage biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment. The company focuses on engineering and manufacturing personalized cell therapies to treat solid tumors. Instil Bio advances multiple TIL therapy candidates through clinical trials targeting various cancer types.